Cochrane Abstracts
Vigabatrin versus carbamazepine monotherapy for epilepsy
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Vigabatrin Versus Carbamazepine Monotherapy for Epilepsy." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434391/all/Vigabatrin_versus_carbamazepine_monotherapy_for_epilepsy.
Vigabatrin versus carbamazepine monotherapy for epilepsy. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434391/all/Vigabatrin_versus_carbamazepine_monotherapy_for_epilepsy. Accessed November 23, 2024.
Vigabatrin versus carbamazepine monotherapy for epilepsy. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434391/all/Vigabatrin_versus_carbamazepine_monotherapy_for_epilepsy
Vigabatrin Versus Carbamazepine Monotherapy for Epilepsy [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 November 23]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434391/all/Vigabatrin_versus_carbamazepine_monotherapy_for_epilepsy.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Vigabatrin versus carbamazepine monotherapy for epilepsy
ID - 434391
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434391/all/Vigabatrin_versus_carbamazepine_monotherapy_for_epilepsy
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
